<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402584</url>
  </required_header>
  <id_info>
    <org_study_id>SB237</org_study_id>
    <nct_id>NCT00402584</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Efficacy and Safety of MeridiaÂ® (Sibutramine Hydrochloride) in Binge-Eating Disorder</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of sibutramine in preventing
      binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of
      sibutramine in reducing body weight in subjects with binge-eating disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency of binge eating episodes (binges/week), defined as the mean number of binges per week in 2-week intervals</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in frequency of binge days (or mean days per week when the participant had one or more binges)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body Weight</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BMI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in global improvement</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in eating pathology (TFEQ)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life (IWQOL-Lite).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">304</enrollment>
  <condition>Binge Eating Disorder</condition>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sibutramine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants were men and women

          -  between the ages of 18 and 65

          -  with Body Mass Index (BMI) &lt;45 kg/m2

          -  who met DSM-IV criteria for BED

        Exclusion Criteria:

          -  Participants were excluded

          -  for blood pressure &gt;140/90 mm Hg

          -  with pulse &gt;95 beats/min

          -  history of stroke, narrow angle glaucoma, cardiac disease, seizures, renal or hepatic
             dysfunction

          -  use of insulin, medications known to affect body weight, or certain psychoactive
             medications (monoamine oxidase inhibitors, lithium, SSRIs, opioids)

          -  current participation in a weight loss program

          -  surgical treatment for obesity

          -  bulimia nervosa or purging in the past 6 months

          -  alcohol or drug abuse in the past 12 months

          -  current psychiatric condition being treated with a psychoactive agent

          -  current major depressive disorder

          -  history of anorexia nervosa, psychosis, bipolar disorder, or suicide attempts

          -  psychotherapy within the previous 2 months

          -  Women were excluded if they were pregnant, lactating, or if fertile, not practicing
             adequate contraceptive precautions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bacher, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>August 30, 2007</last_update_submitted>
  <last_update_submitted_qc>August 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sibutramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

